Toshihiko Tsukada
Overview
Explore the profile of Toshihiko Tsukada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
873
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nagamura Y, Terawaki K, Uezono Y, Tsukada T
BMC Complement Altern Med
. 2014 Jul;
14:256.
PMID: 25038801
Background: Rikkunshito is a traditional Japanese herbal medicine that is used to treat appetite loss associated with cancer and other disorders. The formulation contains various constituents that influence cell signaling,...
2.
Ohki R, Saito K, Chen Y, Kawase T, Hiraoka N, Saigawa R, et al.
Proc Natl Acad Sci U S A
. 2014 Jun;
111(23):E2404-13.
PMID: 24912192
The molecular mechanisms underlying the development of pancreatic neuroendocrine tumors (PanNETs) have not been well defined. We report here that the genomic region of the PHLDA3 gene undergoes loss of...
3.
Horiuchi K, Okamoto T, Iihara M, Tsukada T
Surg Today
. 2012 Oct;
43(8):894-9.
PMID: 23052745
Purpose: To examine the clinical characteristics and survival outcomes of patients with primary hyperparathyroidism (PHPT) in multiple endocrine neoplasia type 1 (MEN1) in relation to the MEN1 gene mutation. Methods:...
4.
Nagamura Y, Yamazaki M, Shimazu S, Tsukada T, Sakurai A
Endocr J
. 2012 Aug;
59(12):1093-8.
PMID: 22878668
Germline MEN1 mutation analysis is a powerful tool for an early diagnosis of multiple endocrine neoplasia type 1 (MEN1), an autosomal dominant familial cancer syndrome characterized by the parathyroid, pituitary...
5.
Nagamura Y, Yamazaki M, Shimazu S, Sano K, Tsukada T, Sakurai A
Endocr J
. 2012 Mar;
59(6):523-30.
PMID: 22447146
Heterozygous germline mutation of the tumor suppressor gene MEN1 is responsible for multiple endocrine neoplasia type 1 (MEN1), a familial cancer syndrome characterized by pituitary, parathyroid and enteropancreatic tumors. Various...
6.
Shimazu S, Shimatsu A, Yamada S, Inoshita N, Nagamura Y, Usui T, et al.
Eur J Endocrinol
. 2011 Dec;
166(3):383-90.
PMID: 22127489
Objective: Dopamine agonists normalize prolactin (PRL) levels and reduce tumour size in responsive prolactinoma. However, several cases have shown resistance to dopamine agonists upon initial treatment. Infrequently, prolactinoma initially responds,...
7.
Shimazu S, Tsukada T
Nihon Rinsho
. 2011 Aug;
69 Suppl 2:593-6.
PMID: 21830607
No abstract available.
8.
Shimazu S, Nagamura Y, Yaguchi H, Ohkura N, Tsukada T
Cancer Sci
. 2011 Aug;
102(11):2097-102.
PMID: 21819486
Germline mutations of the tumor suppressor gene MEN1 are found not only in typical multiple endocrine neoplasia type 1 (MEN1) but also in its incomplete forms such as familial isolated...
9.
Yu D, Nagamura Y, Shimazu S, Naito J, Kaji H, Wada S, et al.
Endocr J
. 2010 Jul;
57(9):825-32.
PMID: 20616437
Menin is lost by the sequential inactivation of both MEN1 alleles in subsets of non-hereditary endocrine tumors as well as those associated with multiple endocrine neoplasia type 1 (MEN1), an...
10.
Kitoh A, Ono M, Naoe Y, Ohkura N, Yamaguchi T, Yaguchi H, et al.
Immunity
. 2009 Oct;
31(4):609-20.
PMID: 19800266
Naturally arising regulatory T (Treg) cells express the transcription factor FoxP3, which critically controls the development and function of Treg cells. FoxP3 interacts with another transcription factor Runx1 (also known...